IL17A and psoriasis: IL-23 inhibitors effectively reduce keratinocyte proliferation and inflammation associated with hidradenitis suppurativa and psoriasis by inhibiting the IL-23/IL-17 axis, therefore affecting the neutrophil recruitment and IL-36 signaling that leads to the pustular eruption [9].